New Streptomyces compound reveals drug breakthrough potential

Scientists discover a first-in-class natural compound with potent drug potential

Scientists have uncovered a new natural compound from the Streptomyces genus, marking a first in its class. The discovery, published in The Journal of Antibiotics, reveals a unique pseudotetrasaccharide structure—unlike any previously known allosamidin congeners. This breakthrough expands the chemical diversity of biologically active molecules with potential drug applications.

The newly identified compound, named N-acetylallosaminylallosamidin, stands out due to its complex pseudotetrasaccharide form. Earlier allosamidin congeners were limited to pseudotrisaccharides, with only four or five variants documented from species like Streptomyces lavendulae and Streptomyces albogriseolus. The additional N-acetylallosamine unit in this congener may enhance its binding to chitinase enzymes, improving both affinity and specificity.

Isolation and characterisation of the molecule relied on advanced analytical techniques, showcasing modern capabilities in natural product chemistry. Testing revealed strong inhibitory effects against mouse acidic mammalian chitinase (AMCase), achieving an IC₅₀ value of 102.3 nanomolar. Such potency suggests promise for drug development, particularly in targeting diseases linked to chitinase activity. The finding also raises questions about the evolutionary origins of Streptomyces' biosynthetic pathways. Researchers now aim to explore how these bacteria assemble extended oligosaccharide chains, potentially unlocking further discoveries in natural product synthesis.

This discovery enriches the chemical toolkit for chitinase inhibitor research while highlighting Streptomyces as a valuable source for novel compounds. The pseudotetrasaccharide's strong inhibitory properties and unique structure position it as a candidate for future drug optimisation. Further study could deepen understanding of its biosynthetic mechanisms and therapeutic potential.